炭疽疫苗
炭疽杆菌
医学
专家意见
重症监护医学
安全概况
接种疫苗
炭疽毒素
生物战
免疫学
免疫
抗体
不利影响
药理学
生物
dna疫苗
毒理
细菌
融合蛋白
基因
生物化学
遗传学
重组DNA
作者
Manish Manish,Shashikala Verma,Divya Kandari,Parul Kulshreshtha,Samer Singh,Rakesh Bhatnagar
标识
DOI:10.1080/14712598.2020.1801626
摘要
Introduction Vaccines and therapeutic antibodies are the most crucial components of anthrax prophylaxis (pre- and post-exposure) and treatment. The improvement in the availability and safety profile of vaccines and the therapeutic antibodies has helped immensely in reducing the worldwide burden of anthrax.Areas covered Current recommendations for anthrax prophylaxis and control, vaccines and therapeutic antibodies, the recent endeavors, particularly, made after 2010 toward making them safer and more efficacious along with our opinion on its future course. Primarily, PubMed and Europe PMC were searched to cover the recent developments in the above-indicated areas.Expert opinion Some key existing lacunae in our understanding of the working of biologicals-based anthrax-control measures, i.e., vaccines and therapeutic antibodies, should be addressed to improve their overall stability, safety profile, and efficacy. The identification of novel inhibitors targeting different key-molecules and vital-steps contributing to the overall anthrax pathophysiology could make a difference in anthrax control.
科研通智能强力驱动
Strongly Powered by AbleSci AI